ORIGINAL ARTICLE Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 Jason D. Goldman, David C.B. Lye, David S. Hui, et al N Engl J Med May 27, 2020DOI: 10.1056/NEJMoa2015301 Abstract BACKGROUND Remdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro and efficacy in animal models of coronavirus disease 2019 (Covid-19). METHODS We conducted a randomized, open-label, phase 3 trial involving hospitalized patients wit...

Research Letter April 27, 2020 Exposure to a Surrogate Measure of Contamination From Simulated Patients by Emergency Department Personnel Wearing Personal Protective Equipment Oren Feldman, Michal Meir, Danielle Shavit, et al JAMA. 2020;323(20):2091-2093. doi:10.1001/jama.2020.6633 A major challenge with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is the effective protection of health care workers.1 Recommendations for t...

ARTICLES|ONLINE FIRST Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial Feng-Cai Zhu, Yu-Hua Li, Xu-Hua Guan, et al Lancet Published:May 22, 2020 DOI: https://doi.org/10.1016/S0140-6736(20)31208-3 Summary Background A vaccine to protect against COVID-19 is urgently needed. We aimed to assess the safety, tolerability, and immunogenicity...

Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis Mandeep R Mehra, Sapan S Desai, Frank Ruschitzka, et al Lancet Published Online May 22, 2020 https://doi.org/10.1016/S0140-6736(20)31180-6 Summary Background Hydroxychloroquine or chloroquine, often in combination with a second-generation macrolide, are being widely used for treatment of COVID-19, despite no conclusive evidence of their...

ORIGINAL ARTICLE Remdesivir for the Treatment of Covid-19 — Preliminary Report John H. Beigel, Kay M. Tomashek, Lori E. Dodd, et al N Engl J Med May 22, 2020DOI: 10.1056/NEJMoa2007764 Abstract BACKGROUND Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), none have yet been shown to be efficacious. METHODS We conducted a double-blind, randomized, placebo-controlled trial of intravenous r...

CORRESPONDENCE Covid-19 and Kidney Transplantation NEJM April 24, 2020DOI: 10.1056/NEJMc2011117 TO THE EDITOR: Kidney-transplant recipients appear to be at particularly high risk for critical Covid-19 illness due to chronic immunosuppression and coexisting conditions.1 At Montefiore Medical Center, we identified 36 consecutive adult kidney-transplant recipients who tested positive for Covid-19 between March 16 and April 1, 2020. A total of 26 recipients (...

Research Letter May 15, 2020 Use of Prone Positioning in Nonintubated Patients With COVID-19 and Hypoxemic Acute Respiratory Failure Xavier Elharrar, Youssef Trigui, Anne-Marie Dols, et al JAMA. Published online May 15, 2020. doi:10.1001/jama.2020.8255 Patients with coronavirus disease 2019 (COVID-19) are at risk for acute respiratory distress syndrome.1 In intubated patients with severe acute respiratory distress syndrome, early and prolonged (...

April 14, 2020 Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial Nina Singh, Drew J. Winston, Raymund R. Razonable, et al. JAMA. 2020;323(14):1378-1387. doi:10.1001/jama.2020.3138 Abstract Importance Despite the use of a cytomegalovirus (CMV) prevention strategy of antiviral prophylaxis for high-risk CMV-seronegative ...

Viewpoint April 6, 2020 The COVID-19 Pandemic in the USA: Clinical Update Saad B. Omer, Preeti Malani, Carlos del Rio JAMA. 2020;323(18):1767-1768. doi:10.1001/jama.2020.5788 Since the first US case of coronavirus disease 2019 (COVID-19) infection as identified in Washington State on January 20, 2020, more than 235 000 cases have been identified across the US in just over 2 months. Given the challenges in expanding testing capacity and the restrictive cas...

Delayed versus early initiation of renal replacement therapy for severe acute kidney injury: a systematic review and individual patient data meta-analysis of randomised clinical trials Lancet 2020; 395: 1506-1515 Summary Background The timing of renal replacement therapy (RRT) for severe acute kidney injury is highly debated when no life-threatening complications are present. We assessed whether a strategy of delayed versus early RRT initiation affects 28-day ...